B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT

Introduction. Despite major therapeutic advances, including T-cell–engaging therapies, most patients with multiple myeloma (MM) eventually relapse. An increasing number of patients are presenting with disease refractory to CD38-targeting antibodies, two immunomodulatory drugs (IMiDs), two proteasom...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	C. Riedhammer, M. Truger, H. Lee, L.B. Leypoldt, M. Meggendorfer, S. Hutter, H. Müller, J. Mersi, S.K. Kadel, T. Buchwald, R. Kosch, M. Helal, N. Afrin, A. Rosenwald, E. Gerhard-Hartmann, A. Brioli, J. Krönke, T. Haferlach, C. Haferlach, K.C. Weisel, P. Neri, H. Einsele, K.M. Kortüm, J.M. Waldschmidt, N. Bahlis, N. Weinhold, L. Rasche
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Ferrata Storti Foundation 2026-04-01
Cyfres:	Haematologica
Mynediad Ar-lein:	https://haematologica.org/article/view/14087
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!